Glenmark Can't Start Selling MS Drug Amid Biogen Fight
Glenmark has failed to shake off a sales ban and a $1 million fine over its multiple sclerosis treatment after a Swedish appellate court ruled that it couldn't market the generic...To view the full article, register now.
Already a subscriber? Click here to view full article